TOKYO, Oct. 8, 2024 /PRNewswire/ — Ciconia Bioventures Inc. (Consultant Director, Founder CEO: Toshio Fujimoto, “Ciconia”) right this moment introduced its institution as a three way partnership firm based mostly on a grasp settlement signed on April 22, 2024 by Takeda Pharmaceutical Firm (NYSE:) Restricted (TSE: 4502/NYSE: TAK, President and CEO, Christophe Weber, “Takeda”), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), and Sumitomo Mitsui (NYSE:) Banking Company (President & CEO: Akihiro Fukutome, “SMBC”). (Information launch concerning the grasp settlement is right here.)
Ciconia seamlessly covers the whole course of from early drug discovery analysis to institution of biotech startups, with the purpose of translating modern applied sciences and drug discovery applications originating in Japan into scientific purposes. Leveraging a variety of promising drug discovery seeds from Japanese academia, biotech startups, and pharmaceutical firms, the corporate will deal with formulating improvement methods and buying new information to boost the worth of those seeds, reworking them into high-potential property with a better probability of success. The corporate will even combine further R&D funding and skilled administration groups to launch new modern startups, rising the variety of profitable biotech ventures rising from Japan. To attain these targets of advancing modern drug discovery applications primarily originating from Japan into the worldwide pharmaceutical market, incubating globally aggressive drug discovery know-how, and fostering entrepreneurship, Ciconia’s incubation actions will likely be carried out in collaboration with academia, biotechnology ventures, and pharmaceutical firms throughout Japan, in a shared effort to unleash the potential of drug discovery ecosystem for the world.
“Ciconia will evaluate early development stage seeds, establish its own company based on the selected seeds, raise funds worldwide and pursue global product development,” stated Toshio Fujimoto, Consultant Director, Founder CEO at Ciconia. “Finally, we hope to ship improvements from Japan to the world by means of our work.”
“The establishment of Ciconia is a significant step forward for the further growth of Japan’s drug discovery ecosystem to lead global R&D,” stated Yasushi Kajii, Head of R&D Japan Area at Takeda. “Leveraging our extensive experience in supporting venture companies and entrepreneurs both domestically and internationally, we are committed to supporting startups emerging from Ciconia with excellent drug discovery seeds to expand globally.”
“We highly expect that Ciconia will activate Japan’s drug discovery ecosystem in collaboration with a wide variety of players from industry, government, and academia, and deliver innovative therapeutics to patients around the world through its global expansion,” stated Issei Tsukamoto, Ph.D., Head of Business Growth, Astellas. “We will provide multifaceted support to Ciconia based on our drug discovery and business expertise, and networks we have cultivated worldwide.”
“We are going to assist Japan’s resurgence by promoting the development of new technologies and industries through Ciconia Bioventures Inc., which aids in the development of new pharmaceuticals,” added a consultant for SMBC.
About Ciconia Bioventures Inc.
Location:
- Headquarter: 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-0012, Japan
- Tokyo Workplace: 3-11-5, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, Japan
Based: August 2024
Capital: Roughly 600 million yen (together with capital reserve)
Administration Crew:
- Consultant Director, Founder CEO: Toshio Fujimoto
- COO/CBO: Masaharu Tani
- Interim CSO: Yoshinori Ikeura
Homepage: https://www.ciconiabioventures.com
